Earnings review: Microsoft, Alphabet, AMD, and Novo Nordisk

Earnings review: Microsoft, Alphabet, AMD, and Novo Nordisk

Equities 5 minutes to read
Peter Garnry

Chief Investment Strategist

Summary:  Microsoft, Alphabet and Novo Nordisk all delivered strong quarterly results. Microsoft's cloud business is growing rapidly, Alphabet's advertising revenue is strong, and Novo Nordisk's weight loss drugs are in high demand. AMD missed on its Q1 revenue guidance, which sent its shares down 6%. Investors are nervous that AMD's results are a warning of a potential slowdown for Nvidia.


Microsoft is in a leading position on AI application execution

The world’s most valuable company delivered a strong quarterly result with revenue increasing 18% y/y and EPS of $2.97 up 28% y/y as its global distribution with the corporate sector continues to give Microsoft an edge in execution on generative AI on the application side. Cloud revenue was $33.7bn vs est. $32.2bn and the company said that AI boosted revenue growth by 6%. From a broader macro perspective Microsoft hinted that capital expenditures will increase materially in the current quarter from the previous quarter as demand for AI related services drives a lot of investments in datacentres. While investors were generally a bit disappointed on growth from Microsoft, but also Alphabet and AMD (see below), the overall conclusion is that growth remains robust and that the outlook is positive which should bode well for equity sentiment going forward.

Strong result from Alphabet bodes well for the economic outlook

Although investors were negative last night after Alphabet announced its Q4 earnings result the company delivered its fourth straight quarter of increasing revenue growth hitting 13.5% y/y in Q4. The EBIT margin expanded for the third straight quarter. The combination of rising revenue growth and expanding EBIT margin are powerful for equity sentiment. The increased focus on raising profitability at Alphabet is paying off and the company is now consistently delivering around 27% EBIT margin up from around 20% before the pandemic.

While Alphabet missed a bit on its advertising revenue relative to estimates the absolute numbers are good and from a macro perspective they suggest companies have a positive outlook for global demand. Advertising is a pro-cyclical indicator. One of the positive surprises were the cloud business revenue coming in at $9.1bn vs est. $9bn as the generative AI push by companies bolstered demand in Google’s cloud services.

Novo Nordisk records highest growth rate in more than 20 years

Novo Nordisk smashed all records in Q4 2023 beating estimates for FY2023 revenue and EBIT. The revenue growth rate in Q4 2023 was 37% y/y the highest recorded growth rate since 2003. This is a big achievement since the company has grown considerable in size over the past 20 years. It highlights the insatiable demand for weight loss drugs and that the growth is not demand constrained but production capacity constrained. This is also seen in the revenue mix with the obesity care segment seeing declining revenue q/q in Q4. The sales mix has shifted from Wegocy, the FDA approved weight loss drug, to Ozempic which is FDA approved for treating type 2 diabetes but contains the same active ingredient, semaglutide, which is a GLP-1 receptor, which causes weight loss.

The revenue guidance for FY2024 is 18-26% which means that the mid-point is a bit below consensus estimate of 23.3%, but given the shares are almost 2% higher it indicates that the market believes that upside surprises could occur this year. The CEO comment that growth can be sustained despite competition is strong forward-looking statement by Novo Nordisk that cement its position as the most valuable company Europe. Novo Nordisk’s results also confirms the investment boom that is currently ongoing in the global technology and health care sectors.

Is AMD guidance a warning for Nvidia?

AMD is playing catchup with Nvidia in delivering advanced AI chips for training of generative AI models. Q4 revenue at $6.2bn was slightly above estimates and adjusted operating income was in line with estimates. The Q1 revenue guidance of $5.1-5.7bn vs est. $5.8bn was a big disappointment for investors sending its shares down 6%. Despite this weaker than estimated outlook AMD did everything it could to paint a picture growth acceleration in AI chips during the FY2024 as the company will roll out new products. Nvidia shares are indicated down in the US pre-market session, suggesting the market is nervous that AMD’s results are a warning of a potential slowdown for Nvidia which reports earnings on 21 February.
AMD share price | Source: Saxo

Quarterly Outlook

01 /

  • Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Quarterly Outlook

    Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Althea Spinozzi

    Head of Fixed Income Strategy

  • Equity Outlook: Will lower rates lift all boats in equities?

    Quarterly Outlook

    Equity Outlook: Will lower rates lift all boats in equities?

    Peter Garnry

    Chief Investment Strategist

    After a period of historically high equity index concentration driven by the 'Magnificent Seven' sto...
  • FX Outlook: USD in limbo amid political and policy jitters

    Quarterly Outlook

    FX Outlook: USD in limbo amid political and policy jitters

    Charu Chanana

    Chief Investment Strategist

    As we enter the final quarter of 2024, currency markets are set for heightened turbulence due to US ...
  • Commodity Outlook: Gold and silver continue to shine bright

    Quarterly Outlook

    Commodity Outlook: Gold and silver continue to shine bright

    Ole Hansen

    Head of Commodity Strategy

  • Macro Outlook: The US rate cut cycle has begun

    Quarterly Outlook

    Macro Outlook: The US rate cut cycle has begun

    Peter Garnry

    Chief Investment Strategist

    The Fed started the US rate cut cycle in Q3 and in this macro outlook we will explore how the rate c...
  • FX: Risk-on currencies to surge against havens

    Quarterly Outlook

    FX: Risk-on currencies to surge against havens

    Charu Chanana

    Chief Investment Strategist

    Explore the outlook for USD, AUD, NZD, and EM carry trades as risk-on currencies are set to outperfo...
  • Equities: Are we blowing bubbles again

    Quarterly Outlook

    Equities: Are we blowing bubbles again

    Peter Garnry

    Chief Investment Strategist

    Explore key trends and opportunities in European equities and electrification theme as market dynami...
  • Macro: Sandcastle economics

    Quarterly Outlook

    Macro: Sandcastle economics

    Peter Garnry

    Chief Investment Strategist

    Explore the "two-lane economy," European equities, energy commodities, and the impact of US fiscal p...
  • Bonds: What to do until inflation stabilises

    Quarterly Outlook

    Bonds: What to do until inflation stabilises

    Althea Spinozzi

    Head of Fixed Income Strategy

    Discover strategies for managing bonds as US and European yields remain rangebound due to uncertain ...
  • Commodities: Energy and grains in focus as metals pause

    Quarterly Outlook

    Commodities: Energy and grains in focus as metals pause

    Ole Hansen

    Head of Commodity Strategy

    Energy and grains to shine as metals pause. Discover key trends and market drivers for commodities i...
Disclaimer

The Saxo Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo or its affiliates.

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK Limited (“Saxo”) is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo holds a Type 1 Regulated Activity (Dealing in Securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged Foreign Exchange Trading); Type 4 Regulated Activity (Advising on Securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products may result in your losses exceeding your initial deposits. Saxo does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo does not take into account an individual’s needs, objectives or financial situation. Please click here to view the relevant risk disclosure statements.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-hk/about-us/awards.

The information or the products and services referred to on this site may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and services offered on this website are not directed at, or intended for distribution to or use by, any person or entity residing in the United States and Japan. Please click here to view our full disclaimer.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc. Android is a trademark of Google Inc.